US OptionsDetailed Quotes
IMMP241220C7500
- 0.00
- 0.000.00%
15min DelayClose Nov 22 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV289.61%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma7.70Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Immutep Stock Discussion
Immutep Ltd (AU:IMM) has released an update.
Immutep Limited announced that all resolutions proposed at their 2024 Annual General Meeting were successfully passed, showcasing strong shareholder support. The company, a leader in LAG-3 immunotherapy for cancer and autoimmune diseases, continues to focus on advancing its innovative treatment options. This positive outcome is likely to strengthen investor confidence and potentially i...
The lead candidate will be evaluated in the phase 3 TACTI-004 trial to investigate its use in patients with first-line non-small cell lung cancer. The trial is set to start later in the year or early next year, the filing said.
The biotechnology f...
Add AU:IMM to your watchlist
Immutep Ltd has witnessed a notable increase in its voting power, with Regal Funds Management Pty Limited and its associates now holding 11.79% of the company’s shares, up from 10.59%. This shift, involving various financial entities like UBS and Merrill Lynch, highlights a growing interest in Immutep’s market potential. Investors keen on stock dynamics should keep an eye on these developments for future implications.
Immutep (IMMP) announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in combination with radiotherapy plus KEYTRUDA for patients with soft tissue sarcoma, STS, at the Connective Tissue Oncology Society, CTOS, 2024 Annual Meeting. Based on preliminary analysis among 21 patients available for primary endpoint assessment, the triple combination therapy demonstrates significant efficacy in the neoadjuvant se...
The study results, with a minimum follow-up of 22 months, showed a median overall survival of 32.9 months, a median progression-free survival o...
Immutep Ltd has unveiled promising Phase II trial results for its novel combination therapy involving eftilagimod alpha, pembrolizumab, and radiotherapy in treating soft tissue sarcoma. The trial demonstrated a significant increase in tumor hyalinization, suggesting improved outcomes and survival rates for patients. With over 71% of participants showing a pathologic response, the therapy showcases potential in addressing thi...
Benzinga· just
Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it will present new data from Cohort B of the TACTI-003 Phase IIb trial in first line recurrent/metastatic head and neck squamous cell carcinoma patient...
No comment yet